

# **Malignant Mesothelioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034**

<https://marketpublishers.com/r/M642CA637960EN.html>

Date: May 2024

Pages: 135

Price: US\$ 6,499.00 (Single User License)

ID: M642CA637960EN

## **Abstracts**

The 7 major malignant mesothelioma markets reached a value of US\$ 6.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 12.2 Billion by 2034, exhibiting a growth rate (CAGR) of 6.5% during 2024-2034.

The malignant mesothelioma market has been comprehensively analyzed in IMARC's new report titled "Malignant Mesothelioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Malignant mesothelioma refers to a rare and aggressive form of cancer characterized by the uncontrolled growth of abnormal cells in the mesothelium, a protective tissue that lines many of the body's internal organs. As the cancerous cells multiply and accumulate, they can form tumors, impair organ function, and spread to various other parts of the body (metastasize). The symptoms of the illness can vary depending on the affected area, but common signs include chest pain, shortness of breath, cough, fatigue, abdominal swelling and pain, weight loss, bowel obstruction, weakness, etc. The diagnosis of malignant mesothelioma is typically made by reviewing a patient's clinical features, medical history, and physical examination. Numerous imaging studies, like computed tomography (CT) scans, chest X-rays, positron emission tomography (PET) scans, etc., are recommended to visualize the presence of abnormal growths and their location. The healthcare provider may also conduct blood tests to evaluate certain biomarkers, such as soluble mesothelin-related peptides and fibulin-3, that may be indicative of the condition. Furthermore, a tissue biopsy is performed to confirm the presence of mesothelioma and determine its type.

The increasing cases of exposure to asbestos fibers, which release reactive oxygen species and inflammatory molecules that can damage DNA within the cells, are

primarily driving the malignant mesothelioma market. In addition to this, the rising incidence of variations in tumor suppressor genes that are responsible for inhibiting cell division and promoting apoptosis is creating a positive outlook for the market. Moreover, the widespread adoption of photodynamic therapy, since it involves using a photosensitizing agent and light to selectively destroy tumors, thereby alleviating symptoms and improving the quality of life for patients, is further bolstering the market growth. Apart from this, the inflating application of immune checkpoint inhibitors, such as pembrolizumab, nivolumab, ipilimumab, etc., to promote a favorable safety profile with fewer adverse effects is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, which offer a way to overcome drug resistance by targeting specific genetic mutations or signaling pathways involved in resistance mechanisms, is expected to drive the malignant mesothelioma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the malignant mesothelioma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for malignant mesothelioma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the malignant mesothelioma market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the malignant mesothelioma market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the malignant mesothelioma market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current malignant mesothelioma marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the malignant mesothelioma market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the malignant mesothelioma market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the malignant mesothelioma market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of malignant mesothelioma across the seven major markets?

What is the number of prevalent cases (2018-2034) of malignant mesothelioma by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of malignant mesothelioma by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with malignant mesothelioma across the seven major markets?

What is the size of the malignant mesothelioma patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of malignant mesothelioma?

What will be the growth rate of patients across the seven major markets?

### Malignant Mesothelioma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for malignant mesothelioma drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the malignant mesothelioma market?

What are the key regulatory events related to the malignant mesothelioma market?

What is the structure of clinical trial landscape by status related to the malignant mesothelioma market?

What is the structure of clinical trial landscape by phase related to the malignant mesothelioma market?

What is the structure of clinical trial landscape by route of administration related to the malignant mesothelioma market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 MALIGNANT MESOTHELIOMA - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 MALIGNANT MESOTHELIOMA - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 MALIGNANT MESOTHELIOMA - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 MALIGNANT MESOTHELIOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 MALIGNANT MESOTHELIOMA - UNMET NEEDS**

## **10 MALIGNANT MESOTHELIOMA - KEY ENDPOINTS OF TREATMENT**

## **11 MALIGNANT MESOTHELIOMA - MARKETED PRODUCTS**

- 11.1 List of Malignant Mesothelioma Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Yervoy (Ipilimumab) - Bristol Myers Squibb
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets
  - 11.1.2 Opdivo (Nivolumab) - Bristol-Myers Squibb/Ono Pharmaceuticals
    - 11.1.2.1 Drug Overview



- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 MALIGNANT MESOTHELIOMA - PIPELINE DRUGS**

### 12.1 List of Malignant Mesothelioma Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 MTG 201- Momotaro-Gene

- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status

#### 12.1.2 RSO-021 - RS Oncology

- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status

#### 12.1.3 Tremelimumab - AstraZeneca

- 12.1.3.1 Drug Overview
- 12.1.3.2 Mechanism of Action
- 12.1.3.3 Clinical Trial Results
- 12.1.3.4 Safety and Efficacy
- 12.1.3.5 Regulatory Status

#### 12.1.4 Pembrolizumab - Merck & Co

- 12.1.4.1 Drug Overview
- 12.1.4.2 Mechanism of Action
- 12.1.4.3 Clinical Trial Results
- 12.1.4.4 Safety and Efficacy
- 12.1.4.5 Regulatory Status

#### 12.1.5 Dasatinib - Bristol-Myers Squibb

- 12.1.5.1 Drug Overview
- 12.1.5.2 Mechanism of Action
- 12.1.5.3 Clinical Trial Results
- 12.1.5.4 Safety and Efficacy

#### 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

### **13. MALIGNANT MESOTHELIOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

### **14. MALIGNANT MESOTHELIOMA – CLINICAL TRIAL LANDSCAPE**

#### 14.1 Drugs by Status

#### 14.2 Drugs by Phase

#### 14.3 Drugs by Route of Administration

#### 14.4 Key Regulatory Events

### **15 MALIGNANT MESOTHELIOMA - MARKET SCENARIO**

#### 15.1 Market Scenario - Key Insights

#### 15.2 Market Scenario - Top 7 Markets

##### 15.2.1 Malignant Mesothelioma - Market Size

###### 15.2.1.1 Market Size (2018-2023)

###### 15.2.1.2 Market Forecast (2024-2034)

##### 15.2.2 Malignant Mesothelioma - Market Size by Therapies

###### 15.2.2.1 Market Size by Therapies (2018-2023)

###### 15.2.2.2 Market Forecast by Therapies (2024-2034)

#### 15.3 Market Scenario - United States

##### 15.3.1 Malignant Mesothelioma - Market Size

###### 15.3.1.1 Market Size (2018-2023)

###### 15.3.1.2 Market Forecast (2024-2034)

##### 15.3.2 Malignant Mesothelioma - Market Size by Therapies

###### 15.3.2.1 Market Size by Therapies (2018-2023)

###### 15.3.2.2 Market Forecast by Therapies (2024-2034)

##### 15.3.3 Malignant Mesothelioma - Access and Reimbursement Overview

#### 15.4 Market Scenario - Germany

##### 15.4.1 Malignant Mesothelioma - Market Size

###### 15.4.1.1 Market Size (2018-2023)

###### 15.4.1.2 Market Forecast (2024-2034)

##### 15.4.2 Malignant Mesothelioma - Market Size by Therapies

###### 15.4.2.1 Market Size by Therapies (2018-2023)

###### 15.4.2.2 Market Forecast by Therapies (2024-2034)

- 15.4.3 Malignant Mesothelioma - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Malignant Mesothelioma - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Malignant Mesothelioma - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Malignant Mesothelioma - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Malignant Mesothelioma - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Malignant Mesothelioma - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Malignant Mesothelioma - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Malignant Mesothelioma - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Malignant Mesothelioma - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Malignant Mesothelioma - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Malignant Mesothelioma - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Malignant Mesothelioma - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Malignant Mesothelioma - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Malignant Mesothelioma - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Malignant Mesothelioma - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Malignant Mesothelioma - Access and Reimbursement Overview

## **16 MALIGNANT MESOTHELIOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 MALIGNANT MESOTHELIOMA MARKET - SWOT ANALYSIS**

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

## **18 MALIGNANT MESOTHELIOMA MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Malignant Mesothelioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/M642CA637960EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M642CA637960EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

